Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion related macular oedema : A prospective randomized comparison-Response
| Errataetall: |
CommentOn: Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):650-5. - PMID 24612095 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Clinical & experimental ophthalmology - 47(2019), 5 vom: 17. Juli, Seite 687 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Macky, Tamer A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2S9ZZM9Q9V |
|---|
| Anmerkungen: |
Date Completed 20.03.2020 Date Revised 20.03.2020 published: Print-Electronic CommentOn: Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):650-5. - PMID 24612095 Citation Status MEDLINE |
|---|
| doi: |
10.1111/ceo.13490 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294410252 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294410252 | ||
| 003 | DE-627 | ||
| 005 | 20231225081422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ceo.13490 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0981.xml |
| 035 | |a (DE-627)NLM294410252 | ||
| 035 | |a (NLM)30816598 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Macky, Tamer A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion related macular oedema |b A prospective randomized comparison-Response |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2020 | ||
| 500 | |a Date Revised 20.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):650-5. - PMID 24612095 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Gado, Ahmed S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & experimental ophthalmology |d 2000 |g 47(2019), 5 vom: 17. Juli, Seite 687 |w (DE-627)NLM108564959 |x 1442-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2019 |g number:5 |g day:17 |g month:07 |g pages:687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ceo.13490 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2019 |e 5 |b 17 |c 07 |h 687 | ||